B
Bullisch
Bullisch · 25%ACAD
$26.83
Szenariopreis
$19.250
+0.651 (+3.38%)Zum Schluss
Loading chart…
- Hoch
- 19.280
- Eröffnung
- 18.600
- Volumengewichteter Durchschnittskurs
- 19.01
- Volumen
- 1.64M
- Marktkap.
- 2.70B
- Tief
- 18.490
- Umsatz
- 31.22M
- EV/EBITDA, TTM
- 15.32
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
KI-Analyse of Acadia Pharmaceuticals Inc. (ACAD)
HaltenGiven the current price of $19.78 and a low RSI of 19.24, the stock is oversold but faces significant risks due to recent trial failures and analyst downgrades. The forward P/E ratio of 25.19 suggests that the stock may be overvalued based on future earnings expectations, despite a gross margin of 90.81%.
Analystenbewertungen (10)
+61.92% Aufwärtspotenzial
Kaufen
8 Kaufen
2 Halten
0 Verkaufen
Aktuell: 19.25
Tief
23.00
Durchschnitt
31.17
Hoch
40.00
RBC Capital
Überdurchschnittlich
$36
2026-10-08
RBC Capital
2026-10-08
Kursziel
$36
Überdurchschnittlich
H.C. Wainwright
Kaufen
$33
2026-09-25
H.C. Wainwright
2026-09-25
Kursziel
$33
Kaufen
Needham
Kaufen
$35
2026-09-25
Needham
2026-09-25
Kursziel
$35
Kaufen
Deutsche Bank
Kaufen
$31
2026-09-25
Deutsche Bank
2026-09-25
Kursziel
$31
Kaufen
BMO Capital
Überdurchschnittlich
$34
2026-09-25
BMO Capital
2026-09-25
Kursziel
$34
Überdurchschnittlich
Bewertungskennzahlen
Das aktuelle erwartete KGV von Acadia Pharmaceuticals Inc. (ACAD) beträgt 25.19, verglichen mit dem 5-Jahres-Durchschnitt von 6.19.
Alphio-AI-Kursszenarien für ACAD
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ACAD halten
Event-Zeitleiste
News
6.009-25stocktwitsAnalysts Lower Price Targets for Acadia Pharmaceuticals
2.009-24stocktwitsAcadia Pharmaceuticals Faces Stock Plunge After Remlifanserin Trial Misses Primary Endpoint
8.509-24NewsfilterAcadia Pharmaceuticals Advances Alzheimer’s Drug Development
9.508-31Yahoo FinanceAcadeMedia Reports Strong Q4 Earnings with Record Sales Growth
8.508-24NASDAQ.COMDAYBU Receives EU Approval for Rett Syndrome Treatment
ACAD FAQ – beantwortet von Alphio AI
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Given the current price of $19.78 and a low RSI of 19.24, the stock is oversold but faces significant risks due to recent trial failures and analyst downgrades. The forward P/E ratio of 25.19 suggests that the stock may be overvalued based on future earnings expectations, despite a gross margin of 90.81%.
10 analysts cover ACAD: 8 rate it Buy, 2 Hold and 0 Sell. The average price target is 31.17.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.